Heart failure & cardiomyopathies
Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
Authors' conclusion
Patients with lower LVEF had a distinctive biomarker profile and a higher risk for adverse clinical outcomes vs those with a higher LVEF. There was no significant interaction for the benefit of vericiguat across LVEF tertiles, although the largest signal for benefit in both the primary outcome and HF hospitalizations was noted in tertile 1 (LVEF ≤24%).
Study context
- Population
- Patients with worsening heart failure (HF) and reduced left ventricular ejection fraction (LVEF) in VICTORIA
- Comparison
- Vericiguat across LVEF tertiles
- Primary endpoint
- Primary outcome: CV death or HF hospitalization
Methodological detailssubgroup analysis by LVEF tertile, Mean LVEF 29% ± 8% (range: 5%-45%)
- Subgroup analysis by LVEF tertile
- Mean LVEF 29% ± 8% (range: 5%-45%)
Primary result
As reported in the abstract
Composite outcome (CV death or HF hospitalisation); vericiguat effect by LVEF tertile
Adjusted hazard ratio (95% CI)
LVEF ≤24%
0.79(0.68–0.94)
LVEF 25%-33%
0.95(0.82–1.11)
LVEF >33%
0.94(0.79–1.11)
- Higher composite event rates with lower LVEF
- P < 0.001
Further findings
CV death and HF hospitalisation individually, by LVEF tertile
- No heterogeneity of effect for CV death
- P for interaction = 0.964
- No heterogeneity of effect for HF hospitalisation
- P for interaction = 0.438
Biomarkers by LVEF tertile
- Higher NT-proBNP, hs-CRP and interleukin 6 in lowest LVEF tertile vs other tertiles
Safety
Discontinuation due to adverse events, symptomatic hypotension, or syncope
- Consistent across the range of LVEF
Original publication
Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA. JACC Heart Fail. Published 12 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →